Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Semaglutide via DV3372 vs PDS290
NCT03611322Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Aug 2018
- Primary completion
- Jan 2019
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of semaglutide in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Novo Nordisk. Primary endpoints: Area under the plasma semaglutide concentration-time curve from 0 until last quantifiable measurement at Week 5 and Maximum plasma semaglutide concentration at Week 5. Started Aug 2018; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03611322.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03611322.